Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, January 4, 2023
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
Tue, January 3, 2023
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
Michael Schmidt Upgraded (ADAP) to Strong Buy and Held Target at $5 on, Jan 3rd, 2023
Michael Schmidt of Guggenheim, Upgraded "Adaptimmune Therapeutics plc" (ADAP) to Strong Buy and Held Target at $5 on, Jan 3rd, 2023.
Michael has made no other calls on ADAP in the last 4 months.
There are 3 other peers that have a rating on ADAP. Out of the 3 peers that are also analyzing ADAP, 2 agree with Michael's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Yanan Zhu of "Wells Fargo" Maintained at Hold with Increased Target to $3 on, Monday, November 14th, 2022
- Nick Abbott of "Wells Fargo" Maintained at Hold with Decreased Target to $1.5 on, Tuesday, October 4th, 2022
This is the rating of the analyst that currently disagrees with Michael
- Mara Goldstein of "Mizuho" Upgraded from Hold to Strong Buy and Held Target at $9 on, Wednesday, November 9th, 2022
